Epithelial-mesenchymal transition (EMT) has a major role in cancer progression, as well as normal organ development and human pathology such as organ fibrosis and wound healing. Here, we performed a gene expression array specialized in EMT of colorectal cancer (CRC). From a comprehensive gene expression analysis using epithelial-and mesenchymal-like CRC cell lines, and following the ontology (GO) analysis, SIX1 gene was identified to be an EMT-related gene in CRC. Using SW480 cells stably transfected with a SIX1 expression construct and their control counterparts, we demonstrated that SIX1 overexpression represses CDH1 expression and promotes EMT in CRC. SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression. In primary tumors of CRC, in accord with the functional findings, aberrant expression of SIX1 in cancer cells was observed at the disruption of the basement membrane and at the tumor invasive front, where tumor cells underwent EMT in vivo. Taken together, SIX1 overexpression is suggested to occur in carcinogenesis, and contribute to repression of CDH1 expression and promotion of EMT partly through repression of miR-200-family expression and activation of ZEB1 in CRC.
Introduction
Sporadic colorectal cancer (CRC) is one of the most common types of cancer and a major cause of death worldwide, including the United States and Japan (Jemal et al., 2010 ; http://ganjoho.ncc.go.jp/ public/statistics/backnumber/2009_en.html). Generally in CRC, tumor cells grow in tubular structures and retain an epithelial phenotype, presenting in welldifferentiated adenocarcinomas. In advanced stages, malignant cells metastasize to the lymph nodes or to distant organs. The ability of CRC cells to invade and metastasize renders tumors unresectable and resistant to chemotherapy (Brabletz et al., 2001) .
Epithelial-mesenchymal transition (EMT) has a crucial role in the development of organs and wound healing, and also contributes to human pathology such as organ fibrosis and cancer progression (Thiery et al., 2009; Micalizzi et al., 2010a) . The acquired mortality, invasiveness and progression to distant metastatic organs of malignant cells result from disorganization of the epithelial morphology, leading to an EMT (Thiery, 2002) . The fundamental feature of EMT is often associated with loss of epithelial differentiation and acquisition of mesenchymal-like cellular competence of tumor cells. Furthermore, tumor cells undergoing EMT emerge at the tumor invasion front, switch toward a more aggressive phenotype and develop invasive, and metastatic, characteristics (Brabletz et al., 2001; Thiery et al., 2009) .
Loss of E-cadherin (CDH1) expression is considered to have a crucial role in tumor progression to invasive cancer and is also one of the fundamental hallmarks of undergoing EMT (Perl et al., 1998; Thiery et al., 2009) . Therefore, characterization of CDH1 regulation has provided important insights into the molecular mechanisms implicated in tumor invasion (Peinado et al., 2007) . Furthermore, it is well recognized that transcriptional factors such as SNAI1 (Batlle et al., 2000; Cano et al., 2000) and ZEB1 (Eger et al., 2005) are associated with EMT activation by repression of CDH1 expression. Currently these important EMT drivers, which have a central role in the biological significance to EMT activation, are shown to correlate significantly with poor clinical prognosis in various types of cancers, including CRC (Roy et al., 2005) .
The SIX1 homeoprotein has been implicated in both tumor initiation and tumor progression in many human cancers (Ford et al., 1998; Yu et al., 2004; Ng et al., 2006; Behbakht et al., 2007; Coletta et al., 2008; McCoy et al., 2009; Micalizzi et al., 2009) , although the molecular mechanisms of SIX1 activity and SIX1 targets are not fully understood. SIX1 is known to contribute to tumor formation and metastatic progression by regulating multiple activities of cancer cells, such as genome stability (Coletta et al., 2008) , responsiveness to apoptotic stimuli (Behbakht et al., 2007) , cell proliferation (Coletta et al., 2004) and epithelial differentiation (Micalizzi et al., 2009) . Recently, several studies provide evidence that SIX1 induces EMT to promote tumor development (McCoy et al., 2009) and activate transforming growth factor-b (TGF-b) signaling in mammary cells (Micalizzi et al., 2009; Micalizzi et al., 2010b) . However, the mechanisms of the majority of SIX1-induced activities, including EMT, in cancer cells remain unclear except mammary cells.
In the study presented here, we performed genomewide comprehensive expression analysis followed by gene ontology (GO) analysis comparing the mesenchymal-and epithelial-like cell lines of CRC to identify the significant EMT-related genes in CRC cells. Among the identified candidates, we focused on the functional significance of SIX1, and demonstrated that SIX1 induces EMT through CDH1 repression possibly induced by posttranscriptional ZEB1 activation in CRC cells. Our results shed new light on tumor progression with respect to EMT in CRC.
Results

SIX1 gene is a putative mesenchymal marker in CRC cells
In our panel of CRC cell lines, three lines, DLD-1, HCT15 and HT29, which show the molecular properties of epithelial cells, show expression of CDH1, whereas the SW620 cell line shows high expression of vimentin (VIM) and low expression of CDH1, one of the molecular hallmarks of undergoing EMT, compared with other CRC cell lines, suggesting it to be a mesenchymal phenotype (Buck et al., 2007) . To identify significant EMT-related genes, we comprehensively compared the gene expression profile of one mesenchymal-like cell line (SW620) and three epithelial-like lines (DLD-1, HCT15 and HT29) in a genome-wide manner ( Figure 1a ).
Of all 41 057 genes profiled in an expression array, we identified 2018 genes showing fourfold altered expression in SW620 compared with three epithelial-like cell lines: known mesenchymal markers, such as VIM, fibronectin (FN1), TWIST2 and ZEB1, were observed as upregulated genes, whereas a known epithelial marker, such as CDH1, was observed as a downregulated gene. Among those genes, we focused on 1233 upregulated genes in SW620, and GO analysis of these genes determined that the term cell motion concerning the cellular process, which contains 17 putative EMTrelated genes, including VIM and FN1, was significantly different (Po0.024) between the mesenchymal-and epithelial-like cell lines (Figures 1a and b) . Through quantitative reverse transcription-PCR (RT-PCR) analysis, the results of our microarray-based analyses were validated in 11 genes (Supplementary Table S3 ). Based on these results, we focused on the SIX1 gene, because (a) SIX1 is known to be a transcriptional factor designating as a homeoprotein and essential for development of organs (Zheng et al., 2003; Kumar, 2009) ; and (b) altered expression of this gene is observed in various cancers (Ford et al., 1998; Ng et al., 2006; Behbakht et al., 2007; Coletta et al., 2008; Wan et al., 2008) and induces EMT in mammary cells (Micalizzi et al., 2009) . Subsequent quantitative RT-PCR analysis of a panel of CRC cell lines showed that SIX1 mRNA expression is frequently positive (8/18 lines, 44%; Figure 1c ). The expression level of the SIX1 protein tended to be inversely correlated with that of CDH1 and positively correlated with that of ZEB1, suggesting SIX1 to be positively correlated with the mesenchymal phenotype of CRC (Figure 1d ).
SIX1 is significantly associated with poorer overall survival probability in advanced-stage CRC To examine the significance of SIX1 expression in clinical CRC cases, we then performed immunohistochemical analysis of SIX1 protein expression using 120 primary CRC samples (Supplementary Table S1 and Figure 2a ). SIX1 expression status showed no association with most of clinicopathological parameters except gender (Supplementary Table S1 ). We analyzed the survival rates of 49 patients with CRC at advanced stages (stages III and IV), and identified that high SIX1 expression in tumors was significantly associated with poor overall survival probability (Figure 2b ), although no statistically significant correlation was observed between SIX1 expression status and prognosis in patients with CRC at all stages (n ¼ 120). These findings support that SIX1 expression contributes to the gain of more malignant phenotypes associated with EMT, such as invasive and metastatic phenotypes, in CRC.
SIX1 promotes EMT in SW480 cells
We investigated how SIX1 contributes to EMT in CRC using the SW480 cells stably expressing FLAG-tagged SIX1. We considered SW480 cells to be appropriate for a series of experiments as SW480 cells are known to undergo EMT or MET through SNAI1 or ZEB1 alteration (Spaderna et al., 2006; Hoshino et al., 2009) . SIX1 overexpression in stable transfectants was verified at the mRNA and protein levels, and FLAG-tagged SIX1 localized in the nucleus (Figure 3a and Supplementary Figure S1 ). SIX1-expressing SW480 cells altered their cell morphology into spindle shapes, with reduced CDH1 expression compared with the empty SIX1 promotes EMT in CRC H Ono et al vector-transfected counterparts, which express E-cadherin at the cell surface ( Figure 3a) . Indeed, we confirmed the expression level of CDH1 to be dramatically reduced at the mRNA and protein levels in SIX1-expressing SW480 cells, although increased expression of VIM was observed only at the protein level (Figures 3a and b) . Notably, no difference in the number of living cells (cell viability) was observed between SIX1-expressing SW480 cells and their empty vector-transfected counterparts during 72 h (Supplementary Figure S2 ). To evaluate the functional role of SIX1 overexpression in cell motility in CRC cells, we performed scratch wound-healing assay and Boyden chamber migration/ invasion assay (Figures 3c and d) . SIX1-expressing cells showed faster wound closure and migration through the uncoated membrane in the Boyden chamber compared with their empty vector-transfected counterparts. In addition, cells migrated through the Matrigel-coated membrane (invasion assay) significantly increased among the SIX1-expressing cells, indicating that SIX1 overexpression is crucial for tumor cell motility ( Figures  3c and d) . These results suggested that SIX1 had a crucial role in inducing EMT in SW480 cells.
SIX1 overexpression induces EMT by posttranscriptional ZEB1 activation in SW480 cells
To examine the mechanisms of SIX-induced EMT, we next focused on repressors of CDH1 to regulate its expression. CDH1 repressors can be divided into two groups depending on the effects on the CDH1 promoter (Thiery, 2002; Thiery et al., 2009 ): factors such as Snail1 and ZEB directly bind to the CDH1 promoter and repress transcriptional activity (Peinado et al., 2007) , whereas factors such as Twist, Goosecoid and FOXC2 repress CDH1 transcription indirectly (Yang and Weinberg, 2008 ). As the mRNA expression level of CDH1 was dramatically reduced by ectopically introduced SIX1 (Figure 3b) , direct repressors such as Snail and ZEB seemed to be of interest as factors correlated with SIX1 activation-induced CDH1 downregulation in SW480 CRC cells.
No difference was observed in the mRNA expression levels of SNAI1 and ZEB1 among SIX1-expressing, empty vector-transfected and non-transfected cells, whereas the protein expression level of ZEB1 was increased in SIX1-expressing SW480 cells (Figure 4a In five cell lines, expression of SIX1 and CDH1 protein was observed in a mutually exclusive manner. In SW480 cells, both SIX1 and CDH1 proteins were observed at a lower expression level.
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EMT. CDH1 mRNA and protein expression was restored in SIX1expressing SW480 cells by transient treatment with a ZEB1-specific small interfering RNA (siRNA) mostly to the levels in the empty vectortransfected counterparts (Figures 4b and c) . Notably, CDH1 mRNA expression level was more significantly restored by ZEB1 siRNA treatment in SIX1-expressing cells as compared with that in the empty vectortransfected counterparts, indicating that SIX1-induced EMT depends on ZEB1 activation ( Figure 4c ). In addition, scratch wound-healing and Boydenchamber migration/invasion assays demonstrated that ZEB1 siRNA treatment inhibited cellular motility and invasion, which were increased by SIX1 overexpression (Figure 4d ), mostly to the levels in the empty vectortransfected counterparts, suggesting that SIX1-induced EMT shows dependence on ZEB1 activation similarly in cell motility and invasion. These findings suggested that SIX1 affects CDH1 transcription level, and enhances cell motility and invasion through induction of ZEB1 expression, and induces EMT.
SIX1 overexpression inhibits the transcriptional activity of the miR-200 family in SW480 cells It is known that the miR-200 family inhibits posttranscriptional activation of ZEB1 and has a major role in specifying the epithelial phenotype, whereas ZEB1 inhibits the transcriptional activity of miR-200 family, suggesting that ZEB1 and the miR-200 family reciprocally control each other's expression, and there is a double-negative feedback loop between ZEB1 and the miR-200 family (Bracken et al., 2008; Burk et al., 2008; Wellner et al., 2009; Brabletz and Brabletz, 2010) .
Thus, we examined the expression of the miR-200 family to evaluate whether the SIX1-induced posttranscriptional ZEB1 activation is mediated by altered expression of the miR-200 family. Reduced expression of all members of the miR-200 family (miR-141, miR200a, miR-200b and miR-200c ) was observed in SIX1-expressing SW480 cells compared with their empty vector-transfected counterparts (Figure 5a) .
To test the hypothesis that expression of the miR-200 family is downregulated at the transcriptional level in SIX1-expressing SW480 cells, we performed promoter assay using a reporter construct containing the fragment of the promoter region for the miR- immunoreactivity, the intensity (intensity score: 0 ¼ negative; 1 ¼ weak; 2 ¼ strong, a) and percentage of the total cell population (proportion score: 1o10%, 10% p2p50%, 50%p3) that expressed SIX1 was evaluated for each case. Expression of SIX1 was graded as either high (total of intensity plus proportion scores ¼ 4-5) or low (no staining or total of intensity plus proportion scores ¼ 0-3) using high-power ( Â 200) microscopy. Bars, 100 mm. (b) Kaplan-Meier curves for survival rates of patients at advanced stages (stages III and IV) according to expression of SIX1. SIX1 immunoreactivity in tumor cells was significantly associated with a worse survival rate (P ¼ 0.038, log-rank test). a direct or indirect manner. However, our preliminary analysis using chromatin immunoprecipitation assay The cell layers were carefully wounded using a sterile 200-ml tip and cultured for 30 h. (d) Transwell migration and invasion assays were performed in 24-well modified Boyden chambers without and with Matrigel, respectively. Cells (1 Â 10 5 per well) were transferred into the upper chamber, and migrated or invasive cells on the lower surface of filters were fixed, stained and counted after 48 h of incubation. We assessed invasive potential by calculating an invasion index, which is the ratio of percentage invasion through the Matrigel-coated filters relative to migration through the uncoated filters of test cells over that of the control counterparts. Columns: Mean of three separate experiments, each performed in triplicate. Bars: s.d. *Po0.05 versus empty vector-transfected control (Student's t-test).
with the empty vector-transfected counterparts, without differentially suppressing ZEB1 expression level between SIX1-expressing and empty vector-transfected cells (Figures 5b and c) . Clear mesenchymal-to-epithelial transition (MET) was induced by ectopic miR-200-family transfection in SIX1-expressing SW480 cells (Figure 5d ).
To confirm SIX1-regulated expression of the miR-200 families and ZEB1, we performed loss of endogenous SIX1 experiments in SW480 cells using specific siRNA. SIX1-specific siRNA-treated SW480 cells showed both upregulation of the miR-200 family and downregulation of the ZEB1 protein compared with their control Figures  S4A and B) , although SIX1 siRNA treatment was insufficient to upregulate CDH1 expression (Supplementary Figure S4B ) and induce alteration of cell morphology (data not shown). Consequently, we concluded that SIX1 promotes EMT through miR-200-family silencing-induced ZEB1 activation, although it remains unclear which mechanisms regulate miR-200-family silencing in SIX1-induced EMT.
Characteristics of SIX1 overexpression in primary tumors of human CRC
In paired tumorous and non-tumorous samples in primary cases of CRC, we observed consistent upregulation of SIX1 mRNA in tumorous tissues compared with their non-tumorous tissues (Supplementary Figure  S5A) . To evaluate the role of SIX1 protein expression in human CRC tissues, immunohistochemical analysis using serial sections was performed. SIX1 protein was aberrantly upregulated in tumor cells, whereas normal mucosa showed no expression of SIX1 (Supplementary Figure S5A) . Aberrant SIX1 expression was also observed at the level of the precancerous lesion (50%, 4/8; Supplementary Figure S5B ), suggesting aberrant SIX1 expression to be a common event from adenoma to invasive adenocarcinoma in the tumorigenesis of CRC. Although SIX1 immunoreactivity was widely shown throughout the tumor, predominant expression of SIX1 was clearly observed at the invasive front or the area with disruption of the basement membrane, where tumor cells underwent EMT in vivo (Supplementary Figure S5C) .
In immunohistochemical analysis of primary CRC cases, we then focused on the invasive front, where ZEB1 is known to be dominantly expressed in human CRC cells (Wan et al., 2008) . SIX1 was expressed in both differentiated cells, which were the major component of the primary CRC tumor, and dedifferentiated cancer cells at the invasive front in CRC. On the other hand, expression of ZEB1 and downregulation of E-cadherin were observed predominantly in dedifferentiated tumor cells (Figure 6a ). These findings suggest that SIX1 synergistically induces ZEB1 expression and E-cadherin repression with other factors, resulting in induction of EMT at the tumor invasive front in the progression of CRC.
Discussion
EMT is known to be involved not only in embryonic development but also in cancer progression and metastasis (Thiery, 2002; Thiery et al., 2009; Iwatsuki et al., 2010; Micalizzi et al., 2010a) . Cancer cells undergoing EMT can acquire invasive properties and enter the surrounding stroma, resulting in the creation of a favorable microenvironment for cancer progression and metastasis. Acquisition of EMT features is also known to be associated with recurrence and metastasis after standard chemotherapeutic treatment, indicating EMT to be closely involved in carcinogenesis, invasion, metastasis, recurrence and chemoresistance, although the involvement of EMT and the molecular mechanisms of its process seem to vary greatly among cancer types. In this study, we applied microarray-based expression profiling, which is commonly used to simultaneously compare and contrast heterogeneous groups of human tumors, and greatly facilitates the dissection of highly complex process involving alterations in the expression of a multitude of genes (Khanna et al., 2001) , to identify a set of genes whose enhanced expression is associated with EMT in CRC cells. Among the genes abstracted by GO analysis, we focused on SIX1 and attempted to explore its functional significance in EMT, as well as molecular mechanisms of how this molecule could contribute to EMT. In the study present here, we experimentally demonstrated that overexpressed SIX1 in tumor cell contributes to progression of CRC through induction of EMT, and SIX1-induced EMT was evoked at least partially by activation of ZEB1.
Overexpression of SIX1 is observed in various types of cancer such as hepatocellular carcinoma (Ng et al., 2006) , breast cancer (Kumar, 2009) , ovarian cancer (Behbakht et al., 2007) and cervical cancer (Wan et al., 2008) . In addition, overexpression of SIX1 is likely to be related to progression, invasion or metastasis in some cancers such as hepatocellular carcinoma (Ng et al., 2006) and breast cancer (Coletta et al., 2008) , although understanding of the molecular mechanisms of SIX1 Figure 4 (a) ZEB1 and SNAI1 mRNA (left, bar graphs) and protein (right, western blotting) expression level in SIX1-introduced SW480 cells compared with their empty vector-transfected counterparts. ZEB1 expression was remarkably increased by SIX1 overexpression at the protein level but not at the mRNA level, whereas SNAI1 expression was increased neither at the mRNA nor the protein level by SIX1 overexpression. (b) Effective knockdown of ZEB1 by specific siRNA (siRNA-ZEB1) was confirmed at the protein level in SIX1-expressing SW480 cells. Through knockdown of ZEB1, notably, CDH1 protein expression downregulated by SIX1 overexpression was restored in SW480 cells. (c) Left: effective knockdown of ZEB1 by specific siRNA (siRNA-ZEB1) was confirmed at the mRNA level in SIX1-expressing SW480 cells. Middle and right Effects of siRNA-ZEB1 treatment on CDH1 mRNA expression in SIX1-transfected SW480 cells or the empty vector-transfected counterparts. CDH1 mRNA expression downregulated by SIX1 overexpression was restored by ZEB1 knockdown to the same level as the empty vector-transfected counterparts (middle). In addition, the effect of ZEB1 knockdown on CDH1 mRNA expression level was higher in SIX1-transfected cells compared with the empty vector-transfected counterparts (right). 
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in the pathogenesis of cancer is still limited so far. Cyclin A1 is shown to be a downstream effecter for SIX1 in breast cancer where overexpression of SIX1 promotes cyclin A1 expression, and subsequently increases cell proliferation and progression (Coletta et al., 2004) . Several other oncogenes, including cyclin D1, c-Myc and Ezrin, were shown to be potentially activated by SIX1 (Yu et al., 2006) . Overexpression of SIX1 also induces resistance to TRAIL-mediated apoptosis (Behbakht et al., 2007) or genomic instability (Coletta et al., 2008) . Recent evidence indicated that aberrant SIX1 expression is related to EMT at least distinctively in breast cancer, and the TGF-b signaling pathway, especially type-I TGF-b receptor, was shown to be a potential target of SIX1 for induction of EMT and/or metastasis (McCoy et al., 2009; Micalizzi et al., 2009 Micalizzi et al., , 2010b . Those reports suggest that SIX1 contributes to initiation, progression and/or metastasis by regulating 
multiple activities of the cancer cell through various targets possibly in a tissue-lineage-and/or stagedependent manner. In our analysis, indeed, aberrant SIX1 expression was correlated with poor prognosis in patients with advanced CRC, and experimentally not related to cell proliferation but induced EMT in CRC cells in vitro. SIX1-induced EMT in CRC cells is characterized by CDH1 repression at the mRNA and protein levels, whereas EMT in mammary cells was confirmed by redistribution of CDH1 from the membrane to the cytoplasm, but not by E-cadherin repression at the protein level (Micalizzi et al., 2009 ). In our preliminary data, no phosphorylated SMAD3 protein was induced in SW480 cells by treatment with recombinant TGF-b1 or by introduction of the SIX1 gene (data not shown). According to the reported evidence of CRC (Massague, 1998) , TGF-b signaling is disrupted by mutations occurring in several genes, such as SMAD4 or type-II TGF-b receptor, resulting in no TGF-b responsiveness in CRC. As SIX1 overexpression may modify TGF-b signaling and repress CDH1 expression in CRC, the effects of SIX1 overexpression on CDH1 activity could be different at least between breast cancer and CRC. In SIX1-induced EMT in CRC cells, transcription factors directly repressing CDH1 expression were of much interest as target for SIX1. Among the various known transcription factors of CDH1, transcriptional repressors of CDH1, such as zinc-finger proteins (ZEB1, ZEB2), the bHLH protein (Twist) and the Snail family of zinc-finger proteins (Snail1, Snail2), were reported to be associated with EMT (Batlle et al., 2000; Comijn et al., 2001; Hajra et al., 2002; Eger et al., 2005) . As we have detected almost no expression of ZEB2 and decreased expression of SNAI2 in the SIX1-transfected SW480 cells in our preliminary expression analyses (data not shown), we focused on ZEB1 and SNAI1 (Figure 4a) , and identified SIX1-induced expression of ZEB1 protein without induction of its mRNA in CRC cells, suggesting SIX1 to induce posttranscriptional ZEB1 activation in CRC cells. As it is known that reciprocal repression between ZEB1 and miR-200-family members promotes EMT in cancer cells (Burk et al., 2008) , we also examined correlation between ZEB1 and miR-200-family members. Correlation among SIX1, ZEB1, the miR-200 family and CDH1 is quite complicated, because (a) miR-200-family members were downregulated at the transcriptional level by SIX1 overexpression ( Figure 5a) ; (b) overexpression of miR-200-family members reduced ZEB1 expression equally between SIX1-overexpressing and mock-transfected cells, but induced a greater increase in CDH1 expression in SIX1-overexpressing cells compared with the mock transfectants ( Figures 5b and c) ; (c) ZEB1 knockdown induced a greater increase in CDH1 expression in SIX1-overexpressing cells compared with the mock transfectants ( Figure 4c) ; and (d) the ZEB1 protein was predominantly expressed at the invasive front where CDH1 repression was observed in a mutually exclusive manner in SIX-overexpressing primary CRC cells (Figure 5c ). Taken together, we hypothesized that SIX1 might induce CDH1 inactivation through inhibition of the miR-200 family and induction of ZEB1 activation, and promote EMT in CRC cells (Figure 6b ), resulting in tumor invasion and metastasis to distant organs, although it remains unclear expression inhibit CDH1 expression and induce EMT in CRC cells. As ZEB1 protein expression and CDH1 repression were observed in SIX1-overexpressing primary CRC cells at the invasive front, we speculated that ZEB1, which is synergistically induced by SIX1 and other factors in primary CRC cells, might induce EMT with CDH1 silencing.
how SIX1 inhibits the transcription of the miR-200 family. As SIX1 overexpression induced an increase in ZEB1 protein without a clear increase of ZEB1 mRNA, in spite of a decrease in the expression of miR200 families, SIX1 may also regulate ZEB1 expression at the translational level independent of the miR200s-mediated pathway (Figure 6b ). Although SIX1 expression was observed even at the early stage of CRC in primary cases, aberrant SIX1 expression was followed by ZEB1 activation and CDH1 repression distinctively at the tumor invasive front in invasive cancer, suggesting that other molecules than SIX1 also contribute to regulation of ZEB1. Recently, it was reported that the ZEB1/miR-200 feedback loop controls Notch signaling in cancer cells (Brabletz et al., 2011) : ZEB1 induces the activation of Notch signaling and promotes carcinogenesis in cancer cells. Previously, SIX1 was shown to be implicated in the Notch pathway as well as the TGF-b pathway in noncancerous tissues (Rodriguez et al., 2008) . As ZEB1 is activated through miR-200-family repression by SIX1 in CRC, SIX1 might exert multiple functions through ZEB1-mediated activation/inactivation of various target pathways in normal developmental organogenesis as well as carcinogenesis. These multi-functional roles of SIX1 could explain why this molecule has various roles in cancer initiation and progression in different tissues.
Materials and methods
Cell lines and primary tumors
Among 18 human CRC cell lines, HCT8, LS174T, RKO, SW620 and T84 were purchased from the American Type Culture Collection (Manassas, VA, USA). The other 13 CRC cell lines were obtained and maintained as described elsewhere (Tanami et al., 2005) .
Paired samples of primary CRCs and the corresponding normal colonic mucosa for quantitative RT-PCR were obtained from 72 unrelated patients to be treated at the Tokyo Medical and Dental University Hospital in 2009. Paraffin-embedded specimens of primary CRC for immunohistochemistry were also obtained from 120 patients to be treated at the Tokyo Medical and Dental University Hospital between 2006 and 2007, and relevant clinical and survival data were available for those 120 patients (Supplementary Table  S1 ). Written consent was always obtained in the formal style and after approval by the local ethics committee.
Gene expression array
Analysis of gene expression profile was performed using the 4 Â 44K Human Whole Genome Ver. 2.0 gene expression array (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's instruction. Data extraction and analysis were performed using Feature Extraction Software version 9.0 and the GeneSpring GX10 software (Agilent Technologies), respectively. All samples were analyzed in a duplicate manner.
Quantitative real-time RT-PCR Expression of mRNA was determined using TaqMan Gene Expression Assays (Supplementary Table S2 ; Applied Biosystems, Foster City, CA, USA). Gene expression values are expressed as ratios between genes of interest and an internal reference gene (Hs99999903_m1 for b-actin, ACTB; Applied Biosystems), and subsequently normalized with the value for the control (relative expression level). Each assay was performed in duplicate for each sample.
Western blot analysis
Western blotting was performed as described elsewhere (Tanami et al., 2005) . The anti-SIX1 (HPA001893), anti-FLAG tag and anti-b-actin antibodies were obtained from Sigma (St Louis, MO, USA); the anti-CDH1 (#610181) antibody was from BD Biosciences (San Jose, CA, USA); anti-VIM (SC-58901) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA); and the anti-ZEB1 (#3396S) and antiSnail1 (#3879S) antibodies were from Cell Signaling Technology (Beverly, MA, USA).
Immunohistochemistry
Indirect immunohistochemistry was performed using formalinfixed, paraffin-embedded tissue sections as described elsewhere (Haruki et al., 2010) . Antigens were retrieved by microwave pretreatment in citrate buffer (pH 9.0; Nichirei, Tokyo, Japan). After blocking in 2% normal swine serum and incubation with each antibody overnight, antigen-antibody reactions were visualized using the avidin-biotin-peroxidase complex system (RTU Vectastain Elite ABC Reagent; Vector Laboratories, Burlingame, CA, USA).
Stable transfection growth assay and fluorescent immunocytochemistry Plasmids expressing N-terminally FLAG-tagged SIX1 (pCMV-3Tag1A-SIX1) were obtained by cloning the RT-PCR product of the full coding sequence of SIX1 in-frame along with the 3XFLAG epitope into the eukaryotic expression vector pCMV-3Tag1A (Stratagene, La Jolla, CA, USA). Stable SIX1 transfectants and control counterparts were obtained by introducing pCMV-3Tag1A-SIX1 and pCMV-3Tag1A-empty (mock), respectively, and G418 selection.
For measurements of cell growth, 1 Â 10 4 cells were seeded in 24-well plates. The numbers of viable cells were assessed by the water-soluble tetrazolium salt assay at 24-72 h after seeding (Haruki et al., 2010) .
Fluorescent immunocytochemistry was performed as described elsewhere (Muramatsu et al., 2011) .
Loss of function by siRNA
Loss-of-function analysis was performed using siRNAs (10 nmol/l) targeting SIX1, ZEB1 and negative controls (SIX1 and negative control, Stealth RNAi-GGGCCACGC CAGGAGCUCAAACUAU and Stealth RNAi Negative Control Medium GC Duplex, respectively (Invitrogen, St Louis, MO, USA); and ZEB1 and negative control, SMARTpool #L-006564-01 and #D-00810-10-05, respectively (Dharmacon, Lafayette, CO, USA)), and Lipofectamine RNAiMAX (Invitrogen), according to the manufacturer's instructions.
Scratch wound-healing assay Scratch wound-healing assay was performed as described elsewhere (Haruki et al., 2010) . Confluent cell layers were carefully wounded using a sterile 200-ml tip, washed twice with fresh medium and cultured for 30 h.
Transwell migration and invasion assay
Transwell migration and invasion assay were performed in 24-well modified chambers pre-coated with (invasion) or without SIX1 promotes EMT in CRC H Ono et al
